The FDA placed Biohaven’s BHV-7000 epilepsy program on partial clinical hold, the company disclosed. Regulators paused enrollment after requesting additional information related to preclinical safety, disrupting a development plan that had also drawn attention for being part of a broader deal pipeline. The move is a reminder that regulator feedback on preclinical packages can quickly halt enrollment even when companies anticipate near-term clinical readouts. Biohaven’s next step will be to address the requested safety details and seek hold resolution to restart enrollment.